公开(公告)号：US20250019653A1

公开(公告)日：2025-01-16

申请号：US18896037

申请日：2024-09-25

Applicant: University of Rochester

Inventor： Steven A. Goldman ,  Su Wang

IPC: C12N5/079 ,  A61K9/00 ,  A61K35/30 ,  C12N5/0735

Abstract: The present disclosure relates to a preparation of CD140a/PDGFRα positive cells that comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFRα. The preparation of cells is derived from pluripotent cells that were derived from skin cells, fibroblasts, umbilical cord blood, peripheral blood, bone marrow, or other somatic cells. The cell preparation has an in vivo myelination efficiency that is equal to or greater than the in vivo myelination efficiency of a preparation of A2B5+/PSA-NCAM− sorted fetal human tissue derived oligodendrocyte progenitor cells. Methods of making, isolating and using the disclosed cell preparation are also described.

公开(公告)号：US10450546B2

公开(公告)日：2019-10-22

申请号：US14764507

申请日：2014-02-06

Applicant: UNIVERSITY OF ROCHESTER

Inventor： Steven A. Goldman ,  Su Wang

IPC: C12N5/071 ,  A01N63/00 ,  C12N5/079 ,  A61K9/00 ,  A61K35/30

Abstract: The present disclosure relates to a preparation of CD140a/PDGFRα positive cells that comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFRα. The preparation of cells is derived from pluripotent cells that were derived from skin cells, fibroblasts, umbilical cord blood, peripheral blood, bone marrow, or other somatic cells. The cell preparation has an in vivo myelination efficiency that is equal to or greater than the in vivo myelination efficiency of a preparation of A2B5+/PSA-NCAM−sorted fetal human tissue derived oligodendrocyte progenitor cells. Methods of making, isolating and using the disclosed cell preparation are also described.

公开(公告)号：US12129484B2

公开(公告)日：2024-10-29

申请号：US16659110

申请日：2019-10-21

Applicant: UNIVERSITY OF ROCHESTER

Inventor： Steven A. Goldman ,  Su Wang

IPC: A61K35/30 ,  A61K9/00 ,  C12N5/079 ,  C12N5/0735

CPC classification number: C12N5/0622 ,  A61K9/0085 ,  A61K35/30 ,  C12N5/0606 ,  C12N2506/02 ,  C12N2506/094 ,  C12N2506/45

Abstract: The present disclosure relates to a preparation of CD140a/PDGFRα positive cells that comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFRα. The preparation of cells is derived from pluripotent cells that were derived from skin cells, fibroblasts, umbilical cord blood, peripheral blood, bone marrow, or other somatic cells. The cell preparation has an in vivo myelination efficiency that is equal to or greater than the in vivo myelination efficiency of a preparation of A2B5+/PSA-NCAM− sorted fetal human tissue derived oligodendrocyte progenitor cells. Methods of making, isolating and using the disclosed cell preparation are also described.